Abbott Laboratories stock heads into the open after a 0.4% dip

At the close on September 9, 2026, Abbott Laboratories stock finished at USD 105.29 on the NYSE, down 0.4%. The shares traded between USD 106.86 and USD 104.78, while the broader market also weakened that day.

Abbott Laboratories stock closed at USD 105.29 on the NYSE on September 9, 2026, slipping 0.4% from the prior session. The shares moved between a day high of USD 106.86 and a low of USD 104.78, with trading volume around 6.43 million shares per exchange data.

September 9, 2026 in numbers

Abbott Laboratories Inc. (ISIN US0028241000, NYSE: ABT) ended the September 9, 2026 session at USD 105.29 after opening near USD 105.66. Per historical price data, the stock's intraday range ran from USD 104.78 at the low to USD 106.86 at the high, with roughly 6.43 million shares changing hands. The closing level left Abbott Laboratories about 23 percent below a 52-week high around USD 137.49 that has been cited in recent filings discussion, while the 52-week low near USD 81.97 remained comfortably below the latest close.

Compared with the broader United States equity market, Abbott Laboratories lagged large-cap benchmarks on September 9, 2026. Major indices closed lower that day, and sector-focused commentary has noted ongoing pressure across medical products and health care names, with Abbott Laboratories shares earlier this week trading closer to the lower end of their recent range as investors reassessed growth expectations in the group.

Events to watch today

Today, September 11, 2026, Abbott Laboratories is not scheduled to release quarterly results, and the next major earnings date in publicly available calendars appears later in the year rather than within the coming days. However, several macroeconomic and health care sector developments could influence sentiment toward Abbott Laboratories stock during today's session. Economic calendars list key United States data releases over the next few days, including inflation indicators and consumer metrics that can affect interest-rate expectations and, in turn, valuation multiples for defensive growth companies in health care. In addition, ongoing analyst coverage, such as recently reiterated positive recommendations on Abbott Laboratories by large brokerage houses as reported by The Globe and Mail, remains a background factor as investors weigh Abbott Laboratories' long-term prospects heading into today's trading.